Trial reportESC heart failure2019
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.
Trial report in ESC heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 21 citations in OpenAlex.
- Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.ESC heart failure · 2019Trial
- Prognostic Significance of Estimated Plasma Volume Status in Patients with Heart Failure: A Systematic Review and Meta-Analysis.Acta Cardiologica Sinica · 2026Article
- Observational
- Iron deficiency and supplementation in heart failure.Nature reviews. Cardiology · 2024Review
- Clinical importance of distinguishing true anemia from dilutional pseudo-anemia: Consequences of a 3-year follow-up volume assessment in a heart failure patient.Clinical case reports · 2024Article
- The DZHK research platform: maximisation of scientific value by enabling access to health data and biological samples collected in cardiovascular clinical studies.Clinical research in cardiology : official journal of the German Cardiac Society · 2023Article
- Iron deficiency and cardiovascular disease.European heart journal · 2023Article
- Iron deficiency in heart failure.ESC heart failure · 2021Review
- Estimated plasma volume status in heart failure: clinical implications and future directions.Clinical research in cardiology : official journal of the German Cardiac Society · 2021Review
- One-year change in plasma volume and mortality in the Japanese general population: An observational cohort study.PloS one · 2021Article
- Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting.Internal and emergency medicine · 2021Article
- Short-term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial-IRON trial.ESC heart failure · 2020Article
- The impact of subclinical congestion on the outcome of patients undergoing transcatheter aortic valve implantation.European journal of clinical investigation · 2020Article
- Prevalence and Causes of Anemia in Hospitalized Patients: Impact on Diseases Outcome.Journal of clinical medicine · 2020Article
- Hypovolemia and reduced hemoglobin mass in patients with heart failure and preserved ejection fraction.Physiological reports · 2019Article
- Intravenous iron therapy for patients with heart failure: expanding body of evidence.ESC heart failure · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 6 countries.
Funding
Abstract
aimsIron deficiency worsens symptoms, quality of life, and exercise capacity in chronic heart failure (CHF) and might do so by promoting fluid retention. We assessed whether iron repletion improved congestion in CHF and appraised the prognostic utility of calculated plasma volume status (PVS), a novel index of congestion, in the FAIR-HF data set. METHODS AND
resultsIn FAIR-HF, 459 iron deficient CHF patients were randomized to intravenous ferric carboxymaltose (FCM) or saline and assessed at 4, 12, and 24 weeks. Using weight and haematocrit, we calculated PVS in 436 patients. At baseline, PVS and weight were -5.5 ± 7.7% and 76.9 ± 14.3 kg, with peripheral oedema evident in 35% of subjects. Higher PVS values correlated to other congestion surrogates such as lower serum albumin. At 4 weeks, FCM was associated with greater reductions in weight (0.02) and PVS (P < 0.0001), and a trend for improved peripheral oedema at 24 weeks (0.07). Irrespective of treatment allocation, patients with a decrease in PVS from baseline to week 24 had higher increments in 6 min walking distance (61.4 m vs. 43.5 m, 0.02) and were more likely to improve their NYHA class (33.3% vs. 15.5%, 0.001). A PVS > -4% at baseline predicted worse outcomes even after adjustment for treatment assignment (hazard ratio 1.88, 95% confidence interval 1.01-3.51, 0.046).
conclusionsIntravenous iron therapy with FCM is associated with early reductions in PVS and weight, implying that decongestion might be one mechanism via which iron repletion aids CHF patients. Calculated PVS is of prognostic utility in this cohort.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.